MAP2K7 and neurofibromatosis type 1: Although orally administered MEK inhibitors have shown promise in treating NF1-related tumors, their systemic toxicities and the nonspecific distribution to other organs raise concerns about their long-term safety for the chronic treatment of cNFs (16, 17).